Analysts on Wall Street have predicted that Pfizer and Moderna's Covid-19 vaccine revenues will reach $ 32 billion in 2021 alone.
According to Arabnet, Pfizer and its German partner Biontech are set to make nearly $ 19 billion, according to Morgan Stanley estimates, which indicate that the two companies could That they will generate nearly $ 30 billion in vaccine revenues by the end of 2023.
Pfizer expects to produce up to 1.3 billion doses of its vaccine in 2021, while Moderna expects to manufacture between 500 million and a billion doses.
and investment bank Goldman Sachs estimated that Moderna could generate $ 13.2 billion in revenue from its Corona vaccine, according to the American CNN Network.
while Morgan Stanley Bank said that Pfizer could still generate about $ 975 million in revenue from its vaccine this year, as the company started a week before distributing its vaccine in the United Kingdom. It is estimated that about 50 million doses of the vaccine will be produced before the end of the year.
The company's sales of the vaccine during 2022 and 2023 are estimated at $ 9.3 billion.
This revenue will be split with BioNTech, the German company that developed the vaccine side-by-side.
Johnson & Johnson and AstraZeneca, both developing Covid-19 vaccines, have promised not to make money from sales of their vaccines during the pandemic even though the AstraZeneca pledge could actually end in June 2021.
